Veradermics Inc's Cash & cash equivalent grew by 318.47 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Veradermics Inc's Quick Ratio to 139.85 a new company high.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Veradermics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 37, from total ranking in the first quarter 2026 at 42.

Explain Quick Ratio?
How much Cash & cash equivalents MANE�s has?
What are MANE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MANE Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Dec 31 2024) Q2	Q1
Y / Y Current Liabilities Change	-	-	-	-	-
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	139.85	58.19	15.5	11.25	-
MANE's Total Ranking	# 37	# 42	# 0	#	#
Seq. Current Liabilities Change	74.12 %	-26.62 %	93.98 %	-	-
Seq. Cash & cash equivalent Change	318.47 %	175.48 %	167.24 %	-	-

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 4
Overall Market	# 37

Quick Ratio Statistics
High	Average	Low
139.85	56.2	11.25
(Jun 30 2026)		(Dec 31 2024)

Financial Statements
Veradermics Inc's Current Liabilities	$ 12 Millions	Visit MANE's Balance sheet
Veradermics Inc's Cash & cash equivalent	$ 1,635 Millions	Visit MANE's Balance sheet
Source of MANE's Sales		Visit MANE's Sales by Geography

Cumulative Veradermics Inc's Quick Ratio

MANE's Quick Ratio for the trailling 12 Months

MANE Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Dec 31 2024) 12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	68.81	28.45	14.06	11.25	-
Total Ranking TTM	#	#	#	#
Seq. Current Liabilities TTM Growth	56.81 %	48.42 %	193.98 %	-	-
Seq. Cash & cash equivalent TTM Growth	279.19 %	200.46 %	267.24 %	-	-

Quick ratio ranking by company, industry and sector >> Back to MANE Financial Strength Comparisons >> Go to Compare MANE Quick Ratio to its Competitors

On the trailing twelve months basis MANE Cash & cash equivalent more than doubled by 318.47 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Veradermics Inc's Quick Ratio to 68.81, above MANE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Veradermics Inc. While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents MANE�s has?
What are MANE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 4
Within the Market	# 37

trailing twelve months Quick Ratio Statistics
High	Average	Low
139.85	56.2	11.25
(Jun 30 2026)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Benitec Biopharma Inc	325.45	$ 179.972 Millions	$ 0.553 Millions
Mira Pharmaceuticals Inc	198.75	$ 8.113 Millions	$ 0.041 Millions
Veradermics Inc	139.85	$ 1,635.362 Millions	$ 11.694 Millions
Enliven Therapeutics Inc	116.86	$ 1,654.850 Millions	$ 14.161 Millions
Acrivon Therapeutics Inc	104.48	$ 89.959 Millions	$ 0.861 Millions
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions
Sagimet Biosciences inc	61.23	$ 331.832 Millions	$ 5.419 Millions
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions

Date modified: 2026-09-26T07:43:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.